Tenet (THC) Upgraded to Buy: Here's What You Should Know

Tenet Healthcare (THC) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates; the Zacks Consensus Estimate for Tenet has increased 5.1% over the past three months. The upgrade reflects an improved earnings outlook, potentially driving the stock higher as institutional investors adjust their valuations based on these revised estimates. For the fiscal year ending December 2025, Tenet is expected to earn $12.72 per share.

Analysis

Tenet Healthcare (THC) has been upgraded to a Zacks Rank #2 (Buy), reflecting an upward trend in earnings estimate revisions, which the Zacks methodology considers a primary driver of near-term stock performance. Specifically, the Zacks Consensus Estimate for Tenet has risen by 5.1% over the past three months, signaling growing analyst optimism regarding its earnings potential. While this revision trend is positive, the current consensus earnings per share (EPS) forecast for the fiscal year ending December 2025 stands at $12.72, a figure that is unchanged compared to the prior year's reported EPS, indicating an expectation of flat year-over-year earnings growth for that specific period. Nevertheless, the Zacks Rank upgrade places Tenet in the top 20% of its covered stocks, suggesting that the positive momentum in estimate revisions is seen as a strong indicator of potential stock price appreciation, as institutional investors often react to such trends by reassessing fair value.

Key Decisions for Investors

• Investors should acknowledge Tenet Healthcare's Zacks Rank #2 (Buy) as a positive signal, primarily driven by a 5.1% increase in its consensus earnings estimates over the last three months, suggesting favorable near-term stock momentum.
• A key consideration is that the FY2025 EPS forecast of $12.72, despite recent upward revisions, represents zero growth compared to the reported EPS of the prior year, warranting a balanced view of the company's earnings trajectory.
• Given THC's placement in the top tier of the Zacks-ranked universe based on estimate revision trends, investors may still find it a candidate for outperformance, but should weigh the positive revision momentum against the flat year-ahead absolute EPS growth projection.